{"id":"W4415941414","doi":"10.1016/j.annonc.2025.08.2126","title":"1496P Clinical benefit of camrelizumab (cam) + rivoceranib (rivo) in unresectable hepatocellular carcinoma (uHCC) patients with macrovascular invasion (MVI) and extrahepatic spread (EHS), CARES-310","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Sorafenib; Hepatocellular carcinoma; Overall survival; Complete response; Disease; Survival rate","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003980171,0.0002754088,0.0006333457,0.000159733,0.0001365608,0.0005321872,0.0001649662,0.0003317711,0.003994998],"category_scores_gemma":[0.0009325027,0.000131709,0.0008608749,0.0001506688,0.0001658527,0.0003431451,0.0001792047,0.0008289291,0.0006749816],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004404568,"about_ca_system_score_gemma":0.0004956276,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005939634,"about_ca_topic_score_gemma":0.001824882,"domain_scores_codex":[0.9998406,0.00005783328,0.00001343142,0.00002683407,0.0000190129,0.00004211154],"domain_scores_gemma":[0.9997805,0.00005768488,0.00004667456,0.00001700783,0.00001651893,0.00008159082],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.3287526,0.002282117,0.09516913,0.001258339,0.002654659,0.000936067,0.000104266,0.002763943,0.01680661,0.001073978,0.02254992,0.5256483],"study_design_scores_gemma":[0.1664572,0.1685249,0.5543605,0.0007017918,0.007782553,0.005429925,0.0003715315,0.009858741,0.01120155,0.003981801,0.07117022,0.0001592325],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.970831,0.01506943,0.0002755753,0.00194507,0.0005617972,0.0001200999,0.001391759,0.0001010239,0.009704194],"genre_scores_gemma":[0.9933915,0.001835846,0.0003326653,0.0007583559,0.0003206627,0.00006215191,0.001336133,0.00001058492,0.001952003],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003994998,"threshold_uncertainty_score":0.01336461,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08359350873281653,"score_gpt":0.3355124208049663,"score_spread":0.2519189120721498,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}